0.7267
前日終値:
$0.75
開ける:
$0.7492
24時間の取引高:
3.33M
Relative Volume:
0.91
時価総額:
$104.84M
収益:
$400.57M
当期純損益:
$9.21M
株価収益率:
18.17
EPS:
0.04
ネットキャッシュフロー:
$146.36M
1週間 パフォーマンス:
-28.05%
1か月 パフォーマンス:
-52.81%
6か月 パフォーマンス:
-83.63%
1年 パフォーマンス:
-90.50%
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
名前
Ironwood Pharmaceuticals Inc
セクター
電話
617-621-7722
住所
100 SUMMER STREET, SUITE 2300, BOSTON, MA
IRWD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
IRWD
Ironwood Pharmaceuticals Inc
|
0.7267 | 104.84M | 400.57M | 9.21M | 146.36M | 0.04 |
![]()
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-15 | ダウングレード | Jefferies | Buy → Hold |
2025-04-15 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2025-04-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
2024-09-09 | 開始されました | Leerink Partners | Market Perform |
2024-08-08 | ダウングレード | CapitalOne | Overweight → Equal Weight |
2024-01-17 | 開始されました | Craig Hallum | Buy |
2023-12-14 | 開始されました | Wells Fargo | Overweight |
2023-11-09 | 開始されました | Jefferies | Buy |
2023-09-28 | 開始されました | JMP Securities | Mkt Outperform |
2022-09-02 | 開始されました | CapitalOne | Overweight |
2022-04-22 | 開始されました | Piper Sandler | Overweight |
2020-09-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2020-06-17 | 開始されました | Northland Capital | Outperform |
2019-07-10 | 再開されました | Credit Suisse | Neutral |
2019-03-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2019-02-25 | アップグレード | H.C. Wainwright | Sell → Neutral |
2019-01-24 | アップグレード | JP Morgan | Underweight → Neutral |
2018-11-07 | ダウングレード | Credit Suisse | Outperform → Neutral |
2018-11-07 | ダウングレード | JP Morgan | Neutral → Underweight |
2018-07-23 | 開始されました | H.C. Wainwright | Sell |
2018-05-09 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2018-01-05 | ダウングレード | BofA/Merrill | Buy → Underperform |
2017-12-06 | ダウングレード | Mizuho | Buy → Neutral |
2017-07-21 | ダウングレード | JP Morgan | Overweight → Neutral |
2017-05-03 | 開始されました | Wells Fargo | Outperform |
2017-04-07 | 繰り返されました | Mizuho | Buy |
2017-02-22 | 繰り返されました | Barclays | Equal Weight |
2016-11-04 | 繰り返されました | Mizuho | Buy |
2016-10-24 | 繰り返されました | Wedbush | Neutral |
2016-10-10 | 繰り返されました | Mizuho | Buy |
2016-09-27 | 繰り返されました | WallachBeth | Hold |
すべてを表示
Ironwood Pharmaceuticals Inc (IRWD) 最新ニュース
Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN
Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN
Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN
Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus
Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN
Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Ironwood downgraded at Jefferies on apraglutide-related challenges (IRWD:NASDAQ) - Seeking Alpha
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 - marketscreener.com
Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 - marketscreener.com
Ironwood crashes down as FDA seeks new phase 3 trial - Pharmaphorum
Ironwood (IRWD) Shares Downgraded by Jefferies Following FDA Set - GuruFocus
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock News - GuruFocus
Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | I - GuruFocus
Ironwood To Consider All Options With Apraglutide Setback In SBS - insights.citeline.com
Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize
Ironwood requires new trial for SBS drug approval By Investing.com - Investing.com South Africa
Top Midday Decliners - MarketScreener
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga
Ironwood to considers merger opportunities after FDA setback - The Business Journals
Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Benzinga
Ironwood (IRWD) Faces Financial Uncertainty as Price Target is S - GuruFocus
Ironwood (IRWD) Faces Financial Uncertainty as Price Target is Slashed | IRWD Stock News - GuruFocus
Ironwood: FDA nay on PK means another apraglutide study - BioWorld MedTech
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - BioSpace
Ironwood Pharmaceuticals (IRWD) Considers Strategic Options Afte - GuruFocus
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial By Investing.com - Investing.com India
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial - Investing.com Australia
Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Benzinga
Ironwood Says FDA to Require Additional Phase 3 Trial for Apraglutide; to Explore Strategic Options - MarketScreener
Ironwood Pharma stock down on regulatory hurdle (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharma Provides Update On Apraglutide; Plans Strategic Alternatives - Nasdaq
Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Followin - GuruFocus
Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Following FDA Talks | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com
Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth - Seeking Alpha
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Stock Sentiment: What’s Wall Street Saying? - stocksregister.com
Short Bowel Syndrome Market Growth Projections 2024-2034: - openPR.com
IRONWOOD PHARMACEUTICALS INC SEC 10-K Report - TradingView
Ironwood Pharmaceuticals Inc. (IRWD) reports earnings - qz.com
Ironwood Pharmaceuticals (IRWD) Faces Nasdaq Compliance Deadline - GuruFocus
Ironwood Pharmaceuticals Gets Nasdaq Non-Compliance Notice - MarketScreener
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing - Business Wire
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Charles Schwab Investment Management Inc. Has $8.79 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Irritable Bowel Syndrome Treatment Market Future Business - openPR.com
StockNews.com Downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to Hold - Armenian Reporter
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD): Blank Check On Growth? - Stocks Register
Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $8.60 - Defense World
Ironwood Pharmaceuticals Inc (IRWD) 財務データ
収益
当期純利益
現金流量
EPS
Ironwood Pharmaceuticals Inc (IRWD) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Silver Ronald | Principal Accounting Officer |
Feb 10 '25 |
Sale |
1.76 |
12,048 |
21,204 |
279,655 |
Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 10 '25 |
Sale |
1.76 |
41,269 |
72,633 |
554,007 |
John Minardo | Chief Legal Officer |
Feb 10 '25 |
Sale |
1.76 |
38,938 |
68,531 |
408,132 |
Martini Gregory S. | Chief Financial Officer |
Feb 10 '25 |
Sale |
1.76 |
12,052 |
21,212 |
183,810 |
大文字化:
|
ボリューム (24 時間):